<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78828">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01775046</url>
  </required_header>
  <id_info>
    <org_study_id>MDTVCFRANCE001</org_study_id>
    <nct_id>NCT01775046</nct_id>
  </id_info>
  <brief_title>Valiant Thoracic Stent Graft With the Captivia Delivery System in the Treatment of Descending Thoracic Aortic Diseases (VALIANT CAPTIVIA France)</brief_title>
  <official_title>Post-market Study on Valiant Thoracic Stent Graft With the Captivia Delivery System in the Treatment of Descending Thoracic Aortic Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Endovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Endovascular</source>
  <oversight_info>
    <authority>France: Haute Autorité de Santé Transparency Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the benefits of endovascular technique in terms of
      efficacy and safety of Valiant Thoracic Stent Graft with the Captivia Delivery System in the
      treatment of thoracic aortic disease, in a cohort of patients representative of the
      population treated under real-life conditions of use in France for up to 5 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data regarding the use under routine practice of thoracic aortic stent grafts in France are
      expected by the French National Authority for Health (HAS). Therefore, in its opinion report
      from December 22, 2009, HAS makes the maintenance of reimbursement approval of each stent
      graft dependent on the presentation of results of a specific follow-up study carried out in
      a cohort of patients representative of the French population treated under real-life
      conditions of use. This prospective cohort study must involve patients implanted after
      registration on the LPPR (List of Products and Services qualifying for Reimbursement). The
      results of the follow-up study must be forwarded to the National Committee for Evaluation of
      Medical Devices and Health Technologies (CNEDiMTS) for examination once a year. The
      assessment of this follow-up could lead to the recommendation by CNEDiMTS to continue or
      stop the reimbursement of the concerned stent graft.

      In France, The Valiant Thoracic Stent Graft with the Captivia Delivery System is registered
      on the LPPR for a period of 3 years since January 12, 2011. In order to comply with HAS
      expectations, Medtronic Bakken Research Center is setting up this long term
      non-interventional study on the Valiant Thoracic Stent Graft with the Captivia Delivery
      System.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exclusion of aneurysm, penetrating aortic ulcer (PAU), false lumen or rupture site</measure>
    <time_frame>Through 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Events</measure>
    <time_frame>Through 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>This includes respiratory, neurological, vascular, cardiac, renal, bleeding, visceral and infectious complications and any complication leading to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion to open repair</measure>
    <time_frame>Through 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endovascular or surgical secondary procedures</measure>
    <time_frame>Through 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse device effects</measure>
    <time_frame>Through 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thoracic disease-related mortality</measure>
    <time_frame>Through 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Aortic Aneurysm, Thoracic</condition>
  <condition>Descending Thoracic Aortic Dissection</condition>
  <condition>Penetrating Ulcer</condition>
  <condition>Aorta Thoracic; Traumatic Rupture</condition>
  <condition>Aortic Diseases</condition>
  <arm_group>
    <arm_group_label>DTA patients</arm_group_label>
    <description>160 patients presenting with a disease of descending thoracic aorta(DTA)with an indication for endovascular treatment with Valiant Thoracic Stent Graft with the Captivia Delivery System and who meet the inclusion/exclusion criteria are intended to participate in this non-interventional.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DTA patients (Valiant)</intervention_name>
    <description>Valiant Thoracic Stent Graft Implantation</description>
    <arm_group_label>DTA patients</arm_group_label>
    <other_name>TEVAR</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects diagnosed with a disease of descending thoracic aorta (DTA) and requiring
        endovascular treatment with Stent Graft.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient requiring placement of the Valiant Thoracic Stent Graft for the treatment
             of a disease of his/her descending thoracic aorta.

          -  Patient or holder of parental authority not opposed to the collection and release of
             the personal information required by the study.

          -  Patient or holder of parental authority has consented for study participation and the
             Medtronic approved Data Release Form has been signed and personally dated by patient
             or holder of parental authority and by the investigator.

        Exclusion Criteria:

          -  Patient in whom clinical follow-up will not be possible i.e. patient not able to come
             back for follow-up visits (ex. patient living abroad).

          -  Prior implantation of a thoracic stent graft.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hervé Rousseau, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rangueil, 1 Avenue Jean Poulhes, TSA 50 032, 31059 TOULOUSE Cedex 9, FRANCE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manuel Girard</last_name>
    <phone>+33474370312</phone>
    <email>manuel.girard@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristel Wittebols</last_name>
    <phone>+31433566580</phone>
    <email>kristel.wittebols@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre Becquemin, MD</last_name>
      <phone>+33 (0)1 49 81 24 33</phone>
      <email>jpbecquemin@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Jean-Pierre Becquemin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascal Desgranges, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Allaire, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric Cochennec, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Marzelle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble, Hôpital A. Michallon</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathieu Rodiere, MD</last_name>
      <phone>+33 (0)4 76 76 89 09</phone>
      <email>mrodiere@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Mathieu Rodiere, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric Thony, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Sengel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé de Parly 2</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice De Cassin, MD</last_name>
      <phone>+33 (0)1 39 63 71 39</phone>
      <email>decassin@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Patrice De Cassin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Chirurgical Marie Lannelongue</name>
      <address>
        <city>Le Plessis-Robinson</city>
        <zip>92350</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryad Bourkaïb, MD</last_name>
      <phone>+33(0)1 40 94 86 41</phone>
      <email>rbourkaib@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ryad Bourkaïb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claude Angel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Planché, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe Brenot, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Yves Riou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis Pesteil, MD</last_name>
      <phone>+33 (0)5 55 05 63 91</phone>
      <email>francis.pesteil@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Francis Pesteil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique de la Sauvegarde</name>
      <address>
        <city>Lyon</city>
        <zip>69009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Résidence du Parc</name>
      <address>
        <city>Marseille</city>
        <zip>13010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Timur Abdulamit, MD</last_name>
      <phone>+33 (0)4 91 83 80 72</phone>
      <email>abdulamit.timur1@bbox.fr</email>
    </contact>
    <investigator>
      <last_name>Timur Abdulamit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves Alimi, MD, PhD</last_name>
      <phone>+33 (0)4 91 96 87 04</phone>
      <email>yves.alimi@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Yves Alimi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Hartung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mourad Boufi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthieu Claudel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bianca Dona, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Gaudric, MD</last_name>
      <phone>+33 (0)1 42 17 57 17</phone>
      <email>julien.gaudric@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Julien Gaudric, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc Alsac, MD</last_name>
      <phone>+33 (0)1 56 09 37 49</phone>
      <email>jean-marc.alsac@egp.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Marc Alsac, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Julia, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne, Hôpital Nord</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Pierre Favre, MD, PhD</last_name>
      <phone>+33 (0)4 77 82 83 35</phone>
      <email>j.pierre.favre@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Pierre Favre, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Noël Albertini, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Belledonne</name>
      <address>
        <city>Saint-Martin-d'Hères</city>
        <zip>38400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane Chabert, MD</last_name>
      <phone>+33 (0)4 38 38 02 02</phone>
      <email>stephanechabert@cccva.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane Chabert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Issam Farah, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine Sauguet, MD</last_name>
      <phone>+33 (0)5 61 77 33 62</phone>
      <email>a.sauguet@clinique-pasteur.com</email>
    </contact>
    <investigator>
      <last_name>Antoine Sauguet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Honton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé Rousseau</last_name>
      <phone>+33 (0)5 61 32 28 81</phone>
      <email>rousseau.h@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Hervé Rousseau, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe Lions, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bertrand Saint-lèbes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-Joseph</name>
      <address>
        <city>Trélazé</city>
        <zip>49800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yann Jousset, MD</last_name>
      <phone>+33 (0)2 41 47 71 18</phone>
      <email>yannjousset@orange.fr</email>
    </contact>
    <investigator>
      <last_name>Yann Jousset, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique du Tonkin</name>
      <address>
        <city>Villeurbanne</city>
        <zip>69626</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Jules Delannoy</last_name>
      <phone>+33 (0)4 72 69 50 82</phone>
      <email>pjdel@club-internet.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre-Jules Delannoy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thibault Streichenberger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric Beck, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 16, 2014</lastchanged_date>
  <firstreceived_date>January 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Valiant</keyword>
  <keyword>Captivia</keyword>
  <keyword>Stent Graft</keyword>
  <keyword>Thoracic</keyword>
  <keyword>Aortic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Diseases</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Aortic Aneurysm, Thoracic</mesh_term>
    <mesh_term>Rupture</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
